Impact Biomedical (IBO) Accounts Payables (2022 - 2026)

Impact Biomedical (IBO) has reported Accounts Payables for 5 consecutive years, with $467000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 15.7% year-over-year to $467000.0; the trailing twelve-month figure through Jun 2026 stood at $467000.0 (down 15.7% YoY), and the FY2025 full-year result was $347000.0, down 51.33% from the prior year.
• Accounts Payables grew to $467000.0 in Q2 2026 per IBO's latest filing, from $374000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $1.0 million in Q1 2024 and bottomed at $301000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $628857.1 across 5 years, with a median of $565000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 227.57% in 2024, then plunged 51.33% in 2025.
• Over 5 years, Accounts Payables stood at $539000.0 in 2022, then jumped by 54.36% to $832000.0 in 2023, then slipped by 14.3% to $713000.0 in 2024, then sank by 51.33% to $347000.0 in 2025, then jumped by 34.58% to $467000.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $467000.0, $374000.0, and $347000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.